Blood marker may guide antiviral treatment duration for respiratory infections
NCT ID NCT06668025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether measuring a protein called MxA in the blood can help doctors decide when to stop antiviral drugs in patients with flu or COVID-19. Researchers enrolled 86 adults and compared standard care to MxA-guided treatment. The goal was to see if the test could reduce symptom recurrence and shorten hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MxA blood test
What this could lead to
If successful, this could help doctors personalize antiviral treatment duration, potentially reducing unnecessary drug use and hospital stays.
What could go wrong
This is a small pilot study with only 86 participants, so results may not apply broadly. The MxA test may not reliably guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship hospital
Beijing, Beijing Municipality, 100029, China